How to utilize current guidelines to manage patients with cancer at high risk for heart failure

Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after can...

Full description

Saved in:
Bibliographic Details
Published inCardio-oncology (London, England) Vol. 10; no. 1; pp. 63 - 6
Main Authors Bloom, Michelle, Alvarez-Cardona, Jose A, Ganatra, Sarju, Barac, Ana, Pusic, Iskra, Lenihan, Daniel, Dent, Susan
Format Journal Article
LanguageEnglish
Published England BioMed Central 28.09.2024
BMC
Subjects
Cancer therapy related cardiac dysfunction
Cardio-Oncology
Cardiomyopathy
Guideline directed medical therapy
Heart Failure
Prevention
Review
Prevention
Heart Failure
Cancer therapy related cardiac dysfunction
Guideline directed medical therapy
Cardiomyopathy
Cardio-Oncology
Online AccessGet full text

Cover

Abstract Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
AbstractList Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
Abstract Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
ArticleNumber 63
Author Bloom, Michelle
Barac, Ana
Pusic, Iskra
Ganatra, Sarju
Lenihan, Daniel
Alvarez-Cardona, Jose A
Dent, Susan
Author_xml – sequence: 1
  givenname: Michelle
  surname: Bloom
  fullname: Bloom, Michelle
  organization: Leon H. Charney Division of Cardiology, New York University School of Medicine, NYU Langone Health, New York, NY, USA
– sequence: 2
  givenname: Jose A
  surname: Alvarez-Cardona
  fullname: Alvarez-Cardona, Jose A
  organization: Leon H. Charney Division of Cardiology, New York University School of Medicine, NYU Langone Health, New York, NY, USA
– sequence: 3
  givenname: Sarju
  surname: Ganatra
  fullname: Ganatra, Sarju
  organization: Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Department of Medicine, Beth Israel Lahey Health, Burlington, MA, USA
– sequence: 4
  givenname: Ana
  surname: Barac
  fullname: Barac, Ana
  organization: Inova Schar Heart and Vascular and Inova Inova Schar Cancer, Falls Church, VA, USA
– sequence: 5
  givenname: Iskra
  surname: Pusic
  fullname: Pusic, Iskra
  organization: Division of Oncology, Department of Medicine, Washington University, St. Louis, MO, USA
– sequence: 6
  givenname: Daniel
  surname: Lenihan
  fullname: Lenihan, Daniel
  organization: International Cardio-Oncology Society, FL and Cape Cardiology Group, Cape Girardeau, Tampa, MO, USA
– sequence: 7
  givenname: Susan
  surname: Dent
  fullname: Dent, Susan
  email: Susan.dent@duke.edu
  organization: Duke Cancer Institute, Department of Medicine, Duke University, DUMC 3446, Durham, NC, 27710, USA. Susan.dent@duke.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39342407$$D View this record in MEDLINE/PubMed
BookMark eNpVkc1u1TAQhS1UREvpC7BAXrJJ8b_jFUIVtJUqsYG15TjjxCU3vtgJVXl6fJtStSuPfGa-M6PzFh3NaQaE3lNyTmmrPhVBjDQNYaIhhNVKvkInjEjd8JaIo2f1MTor5ZbULiaEUuoNOuaGCyaIPkH2Kt3hJeF1iVP8C9ivOcO84GGNPUxxhnJQd252A-C9W2IVC76Ly4i9mz1k7BY8xmHEOZZfOKSMR3B5wcHFac3wDr0Obipw9vieop_fvv64uGpuvl9eX3y5abygemlkD0qxrnNGU2kEZaqlWvdOqyA470NwvZdUE0Vk60UAyoOhDrqquVYL4KfoeuP2yd3afY47l-9tctE-fKQ82LpV9BPYwJ1sRXew8aL6GO99MGB4q5UQnFTW5421X7sd9L6enN30AvpSmeNoh_THUip4y4yshI-PhJx-r1AWu4vFwzS5GdJaLKeUGCq3Vra1-pxKyRCefCixh6TtlrStSduHpO1h6MPzDZ9G_ufK_wH0MqZc
Cites_doi 10.1016/j.echo.2014.07.012
10.1093/cvr/cvz026
10.1016/j.jacc.2018.02.037
10.1016/j.jaccao.2022.07.005
10.1002/ejhf.2818
10.1016/j.semcancer.2020.06.005
10.1016/j.jaccao.2019.08.003
10.1016/j.jaccao.2021.06.003
10.1056/NEJMoa1910549
10.1002/ejhf.1920
10.1016/j.cpcardiol.2023.101885
10.1186/s40959-019-0036-7
10.1200/jco.2017.76.3920
10.1158/1078-0432.CCR-20-4621
10.1016/j.jaccao.2022.11.011
10.1016/j.jaccao.2023.03.011
10.1161/cir.0000000000001062
10.1093/eurheartj/ehab674
10.1016/j.ejca.2015.07.031
10.1007/s11864-022-01012-9
10.1093/ehjci/jeac106
10.1056/NEJMoa1812389
10.1093/eurheartj/ehac244
10.1136/jitc-2019-000261
10.1007/s00432-003-0498-7
10.1016/s0140-6736(18)32484-x
10.1016/j.jchf.2022.03.006
10.1161/cir.0000000000000679
10.1093/ehjci/jet123
10.1200/JCO.1997.15.4.1318
10.1056/NEJMoa1611925
10.1016/j.annonc.2019.10.023
10.1056/NEJMoa1504720
10.3390/cancers13174421
ContentType Journal Article
Copyright 2024. The Author(s).
The Author(s) 2024 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: The Author(s) 2024 2024
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1186/s40959-024-00259-5
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2057-3804
EndPage 6
ExternalDocumentID oai_doaj_org_article_f3a584b5941c46819cccf9e938764430
10_1186_s40959_024_00259_5
39342407
Genre Journal Article
Review
GroupedDBID 0R~
7X7
8FI
8FJ
AAFWJ
AAJSJ
ABUWG
ACGFS
ACRMQ
ADBBV
ADINQ
ADUKV
AFKRA
AFPKN
AHBYD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
ASPBG
BCNDV
BENPR
BFQNJ
BMC
C24
C6C
CCPQU
EBLON
EBS
EIHBH
FYUFA
GROUPED_DOAJ
HMCUK
IAO
ITC
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
ROL
RPM
RSV
SOJ
UKHRP
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c417t-5de662bba9715941268177da76f433dffadc51706058c4fe13f91aeb33da874e3
IEDL.DBID RPM
ISSN 2057-3804
IngestDate Tue Oct 22 15:07:09 EDT 2024
Mon Sep 30 11:48:22 EDT 2024
Sat Oct 26 02:11:32 EDT 2024
Wed Oct 02 14:40:14 EDT 2024
Tue Oct 29 09:08:33 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Prevention
Heart Failure
Cancer therapy related cardiac dysfunction
Guideline directed medical therapy
Cardiomyopathy
Cardio-Oncology
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c417t-5de662bba9715941268177da76f433dffadc51706058c4fe13f91aeb33da874e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438295/
PMID 39342407
PQID 3110915295
PQPubID 23479
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_f3a584b5941c46819cccf9e938764430
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11438295
proquest_miscellaneous_3110915295
crossref_primary_10_1186_s40959_024_00259_5
pubmed_primary_39342407
PublicationCentury 2000
PublicationDate 2024-09-28
PublicationDateYYYYMMDD 2024-09-28
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Cardio-oncology (London, England)
PublicationTitleAlternate Cardiooncology
PublicationYear 2024
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References JD Mitchell (259_CR10) 2021; 3
JR Hu (259_CR22) 2019; 115
AR Lyon (259_CR5) 2020; 22
SJH Dobbin (259_CR26) 2023; 25
AR Lyon (259_CR20) 2022; 23
259_CR2
SH Armenian (259_CR4) 2018; 36
C Porter (259_CR34) 2022; 4
H Abdel-Qadir (259_CR28) 2023; 5
SC Gilchrist (259_CR32) 2019; 139
P Schmid (259_CR1) 2020; 382
JC Plana (259_CR19) 2014; 27
259_CR14
F Borri (259_CR33) 2021; 72
P Lancellotti (259_CR8) 2013; 14
259_CR18
BP Halliday (259_CR35) 2019; 393
AR Lyon (259_CR15) 2022; 43
B Zinman (259_CR31) 2015; 373
B Neal (259_CR29) 2017; 377
CA Gongora (259_CR27) 2022; 10
SD Wiviott (259_CR30) 2019; 380
J Herrmann (259_CR3) 2022; 43
N Yamaguchi (259_CR11) 2015; 51
AVS Macedo (259_CR17) 2019; 1
G Curigliano (259_CR9) 2020; 31
BA Van Tine (259_CR16) 2021
GA Suero-Abreu (259_CR21) 2022; 4
259_CR24
SN Badiyan (259_CR7) 2022; 23
259_CR23
S Mahmood (259_CR25) 2018; 71
S Ganatra (259_CR12) 2019; 5
SMVP Swain (259_CR13) 2004; 130
PA Heidenreich (259_CR6) 2022; 145
References_xml – volume: 27
  start-page: 911
  issue: 9
  year: 2014
  ident: 259_CR19
  publication-title: J Am Soc Echocardiogr
  doi: 10.1016/j.echo.2014.07.012
  contributor:
    fullname: JC Plana
– volume: 115
  start-page: 854
  issue: 5
  year: 2019
  ident: 259_CR22
  publication-title: Cardiovasc Res
  doi: 10.1093/cvr/cvz026
  contributor:
    fullname: JR Hu
– volume: 71
  start-page: 1755
  issue: 16
  year: 2018
  ident: 259_CR25
  publication-title: JACC
  doi: 10.1016/j.jacc.2018.02.037
  contributor:
    fullname: S Mahmood
– volume: 4
  start-page: 302
  issue: 3
  year: 2022
  ident: 259_CR34
  publication-title: JACC CardioOncol
  doi: 10.1016/j.jaccao.2022.07.005
  contributor:
    fullname: C Porter
– volume: 25
  start-page: 488
  issue: 4
  year: 2023
  ident: 259_CR26
  publication-title: Eur J Heart Fail
  doi: 10.1002/ejhf.2818
  contributor:
    fullname: SJH Dobbin
– volume: 72
  start-page: 136
  year: 2021
  ident: 259_CR33
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2020.06.005
  contributor:
    fullname: F Borri
– volume: 1
  start-page: 68
  issue: 1
  year: 2019
  ident: 259_CR17
  publication-title: JACC CardioOncol
  doi: 10.1016/j.jaccao.2019.08.003
  contributor:
    fullname: AVS Macedo
– volume: 3
  start-page: 360
  issue: 3
  year: 2021
  ident: 259_CR10
  publication-title: JACC CardioOncol
  doi: 10.1016/j.jaccao.2021.06.003
  contributor:
    fullname: JD Mitchell
– volume: 382
  start-page: 810
  issue: 9
  year: 2020
  ident: 259_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1910549
  contributor:
    fullname: P Schmid
– volume: 22
  start-page: 1945
  issue: 11
  year: 2020
  ident: 259_CR5
  publication-title: Eur J Heart Fail
  doi: 10.1002/ejhf.1920
  contributor:
    fullname: AR Lyon
– ident: 259_CR24
  doi: 10.1016/j.cpcardiol.2023.101885
– ident: 259_CR2
– volume: 5
  start-page: 1
  year: 2019
  ident: 259_CR12
  publication-title: Cardiooncology
  doi: 10.1186/s40959-019-0036-7
  contributor:
    fullname: S Ganatra
– volume: 36
  start-page: 2135
  issue: 21
  year: 2018
  ident: 259_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2017.76.3920
  contributor:
    fullname: SH Armenian
– year: 2021
  ident: 259_CR16
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-4621
  contributor:
    fullname: BA Van Tine
– volume: 4
  start-page: 598
  issue: 5
  year: 2022
  ident: 259_CR21
  publication-title: JACC CardioOncol
  doi: 10.1016/j.jaccao.2022.11.011
  contributor:
    fullname: GA Suero-Abreu
– volume: 5
  start-page: 318
  issue: 3
  year: 2023
  ident: 259_CR28
  publication-title: JACC: CardioOncol.
  doi: 10.1016/j.jaccao.2023.03.011
  contributor:
    fullname: H Abdel-Qadir
– volume: 145
  start-page: e876
  issue: 18
  year: 2022
  ident: 259_CR6
  publication-title: Circulation
  doi: 10.1161/cir.0000000000001062
  contributor:
    fullname: PA Heidenreich
– volume: 43
  start-page: 280
  issue: 4
  year: 2022
  ident: 259_CR3
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab674
  contributor:
    fullname: J Herrmann
– volume: 51
  start-page: 2314
  issue: 16
  year: 2015
  ident: 259_CR11
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.07.031
  contributor:
    fullname: N Yamaguchi
– volume: 23
  start-page: 1388
  issue: 10
  year: 2022
  ident: 259_CR7
  publication-title: Curr Treat Options Oncol
  doi: 10.1007/s11864-022-01012-9
  contributor:
    fullname: SN Badiyan
– volume: 23
  start-page: e333
  issue: 10
  year: 2022
  ident: 259_CR20
  publication-title: Eur Heart J Cardiovasc Imaging
  doi: 10.1093/ehjci/jeac106
  contributor:
    fullname: AR Lyon
– volume: 380
  start-page: 347
  issue: 4
  year: 2019
  ident: 259_CR30
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1812389
  contributor:
    fullname: SD Wiviott
– volume: 43
  start-page: 4229
  issue: 41
  year: 2022
  ident: 259_CR15
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehac244
  contributor:
    fullname: AR Lyon
– ident: 259_CR23
  doi: 10.1136/jitc-2019-000261
– volume: 130
  start-page: 1
  year: 2004
  ident: 259_CR13
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-003-0498-7
  contributor:
    fullname: SMVP Swain
– volume: 393
  start-page: 61
  issue: 10166
  year: 2019
  ident: 259_CR35
  publication-title: Lancet
  doi: 10.1016/s0140-6736(18)32484-x
  contributor:
    fullname: BP Halliday
– volume: 10
  start-page: 559
  issue: 8
  year: 2022
  ident: 259_CR27
  publication-title: JACC Heart Fail.
  doi: 10.1016/j.jchf.2022.03.006
  contributor:
    fullname: CA Gongora
– volume: 139
  start-page: e997
  issue: 21
  year: 2019
  ident: 259_CR32
  publication-title: Circulation
  doi: 10.1161/cir.0000000000000679
  contributor:
    fullname: SC Gilchrist
– volume: 14
  start-page: 721
  issue: 8
  year: 2013
  ident: 259_CR8
  publication-title: Eur Heart J Cardiovasc Imaging
  doi: 10.1093/ehjci/jet123
  contributor:
    fullname: P Lancellotti
– ident: 259_CR14
  doi: 10.1200/JCO.1997.15.4.1318
– volume: 377
  start-page: 644
  issue: 7
  year: 2017
  ident: 259_CR29
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1611925
  contributor:
    fullname: B Neal
– volume: 31
  start-page: 171
  issue: 2
  year: 2020
  ident: 259_CR9
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2019.10.023
  contributor:
    fullname: G Curigliano
– volume: 373
  start-page: 2117
  issue: 22
  year: 2015
  ident: 259_CR31
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1504720
  contributor:
    fullname: B Zinman
– ident: 259_CR18
  doi: 10.3390/cancers13174421
SSID ssj0002244666
Score 2.3224933
SecondaryResourceType review_article
Snippet Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise...
Abstract Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 63
SubjectTerms Cancer therapy related cardiac dysfunction
Cardio-Oncology
Cardiomyopathy
Guideline directed medical therapy
Heart Failure
Prevention
Review
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS8QwEA3iQbyI39YvIniTstsmTZOjirIIelLYW0jTRFekK7tdBH-9M0lXdkXw4rUpaXgvYWYy0zeEnIMH4HJflKmvJF7deJEawQ1EKTl4p7LP6iCZf_8gBk_8blgMF1p9YU1YlAeOwPU8M2Ajq0LxzHIB9sta65VTDI4x5yxG6321EEy9BlEXzFOK-V8yUvSmPNx4gUlK0c6rtFiyREGw_zcv82ex5IL1ud0kG53bSC_jcrfIimu2ydp9lxjfIXow_qDtmMI2eht9Omqj7BJ9nqGMFZa242gsVaWdluqU4iUstcj7hJqWonQxxVpzCp4sxVbXLfVmhIXru-Tp9ubxepB2vRNSy7OyTYvaCZFXlVFlhtjlAF1Z1qYUnjNWe29qWwTpnEJa7l3GvMoMRNasNrLkju2R1WbcuANCpbQwh2Q1433Orao89jZSXNTobfVZQi7mOOr3KJGhQ2ghhY6oa0BdB9R1kZArhPr7TZS3Dg-AdN2Rrv8iPSFnc6I0HAfMcZjGjWdTzVBBNcPsZUL2I3Hfn2KKcQxgEyKXKF1ay_JIM3oJktsZdomHSQ__Y_VHZD0P-1CluTwmq-1k5k7AtWmr07CLvwCumfOa
  priority: 102
  providerName: Directory of Open Access Journals
Title How to utilize current guidelines to manage patients with cancer at high risk for heart failure
URI https://www.ncbi.nlm.nih.gov/pubmed/39342407
https://www.proquest.com/docview/3110915295
https://pubmed.ncbi.nlm.nih.gov/PMC11438295
https://doaj.org/article/f3a584b5941c46819cccf9e938764430
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDsZexr7nfQQN9jbcxJYsS49paQmBlLKtkDchy1KX0dolcRjsr9-dHJdm7GlPBssfh35n63fS6XcAn5EB-DwUZRoqRVM3QaZWCotRSo7sVE14HSXzFxdydiXmy2J5AHLYCxOT9l21Om5ubo-b1Y-YW3l368ZDntj4cnGaUc3uXBfjQzhED30Qo_-Mgi60RimHHTJKjjciznbhcJTSGK9TqlfDNRcUzuwNSFG3_19k8--cyQeD0PkzeLpjj2zaW_kcDnzzAh4vduvjL8HM2l-saxl6083qt2euV19i11tSs6IMd2rtM1bZTlJ1w2guljmCf81sx0jBmFHKOUNCy6jidceCXVH--iu4Oj_7fjpLdyUUUieyskuL2kuZV5XVJfIWkeVSZWVZ21IGwXkdgq1dERV0CuVE8BkPOrMYYPPaqlJ4_hqOmrbxb4Ep5fAZitdcTIRwugpU4kgLWRPpmvAEvgz9aO56pQwTIwwlTQ-AQQBMBMAUCZxQV99fSSrX8US7vjY7rE3gFvlRRYY7gZZr51zQXnP8hQvBJwl8GoAy-FXQUodtfLvdGE5CqhktYibwpgfu_lUD8AmoPUj3bNlvQUeMytuD4737_1vfw5M8OqJOc_UBjrr11n9EXtNVI3TmZTmCR9Pp_NscjydnF5dfR3GWYBRd_A8uofpN
link.rule.ids 230,315,730,783,787,867,888,2109,27938,27939,31734,33759,53806,53808
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB1RKrVc-l0aWoor9VZlN4kdxz5SBNoWFvUAKjfLcWy6LSRoN6tK_Pp6nASxiAu9xvmwM2PNG_v5DcBnjwBs5vIidqXApRvHY82Z9llK5tGpSGgVJPOnx3xyyr6f5WdrwIezMIG0b8rZqL64HNWzX4FbeXVpxgNPbPxjupdize5M5uNH8NhP2ITfytJ_B0kX3KXkwxkZwccLFta7fECKMcrLGCvWUEkZJjQrISko998HN--yJm-FoYPn8HMYQMc--TNatuXIXN_Rdnz4CF_Asx6Zkt2u_SWs2foVPJn2e--vQU2av6RtiPfUi9m1JaZTdiLnS1TKQvY8tnZsWNLLtS4IrvMSg641J7olqI5MkM5OPFgmWE27JU7PkBv_Bk4P9k_2JnFfniE2LC3aOK8s51lZall4TMTSjIu0KCpdcMcorZzTlcmDOk8uDHM2pU6m2ifvtNKiYJa-hfW6qe07IEIY_w5BK8oSxowsHZZPkoxXCOgSGsGXwULqqlPhUCF7EVx1plXetCqYVuURfEUj3tyJCtrhQjM_V_1fVo5qj71K7LhhvufSGOOkldSHB8ZoEsGnwQWUn3G4jaJr2ywXiqJIa4obpBFsdi5x86nBpSIQK86y0pfVFu8CQdV7MPnW_z-6A08nJ9MjdfTt-PA9bGTB3WWciQ-w3s6Xdtvjp7b8GCbLP22HF4Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkSouvGnD00jcUDYPO459hMJqeWzVA5UqcbAcxy5L22S1mxVSfz0eJ6m6FadeYyexM2PNN_aXbwDeewRgc1eUsasEbt04HmvOtM9Sco9ORUrrIJk_P-SzY_btpDgZWJXrgVbZmGoxac4vJs3id-BWLi9MMvLEkqP5QYY1u3NZJMvaJXfhnl-0qbiWqf8Jsi54UsnH_2QET9Ys7Hn5oBRjpJcxVq2hkjJMarbCUlDv_x_kvMmcvBaKpg_h1ziJnoFyNtl01cRc3tB3vN0sH8GDAaGSj32fx3DHNk9gdz6cwT8FNWv_kq4l3mPPF5eWmF7hiZxuUDELWfTY2rNiySDbuia430sMutiK6I6gSjJBWjvxoJlgVe2OOL1AjvwzOJ5--Xkwi4cyDbFhWdnFRW05z6tKy9JjI5blXGRlWeuSO0Zp7ZyuTRFUegphmLMZdTLTPomntRYls_Q57DRtY_eBCGH8MwStKUsZM7JyWEZJMl4jsEtpBB9GK6llr8ahQhYjuOrNq7x5VTCvKiL4hIa86olK2uFCuzpVw5dWjmqPwSocuGF-5NIY46SV1IcJxmgawbvRDZRfeXicohvbbtaKolhrhgelEez1bnH1qtGtIhBbDrM1lu0W7wZB3Xs0-4vb3_oWdo8-T9WPr4ffX8L9PHi8jHPxCna61ca-9jCqq96E9fIPPloaBA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=How+to+utilize+current+guidelines+to+manage+patients+with+cancer+at+high+risk+for+heart+failure&rft.jtitle=Cardio-oncology+%28London%2C+England%29&rft.au=Bloom%2C+Michelle&rft.au=Alvarez-Cardona%2C+Jose+A&rft.au=Ganatra%2C+Sarju&rft.au=Barac%2C+Ana&rft.date=2024-09-28&rft.issn=2057-3804&rft.eissn=2057-3804&rft.volume=10&rft.issue=1&rft.spage=63&rft_id=info:doi/10.1186%2Fs40959-024-00259-5&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2057-3804&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2057-3804&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2057-3804&client=summon